Industry observers believe a final FDA decision could significantly influence: Compounding pharmacies Telehealth providers Peptide manufacturers Researchers Physicians Patients seeking compounded therapies Because of this potential impact, the advisory meeting received substantial attention across the healthcare and biotechnology industries
Long-term human studies are still limited, which is why clinician oversight and ongoing monitoring are important
Ishak IH, Kamgang B, Ibrahim SS, Riveron JM, Irving H, Wondji CS
Inflammopharmacology 32, 25052524
It regulates neuronal excitability, synaptic plasticity, and mood-related behaviors in laboratory models
Involvement of the 55- and 75-kDa tumor necrosis factor receptors in the generation of lymphokine-activated killer cell activity and proliferation of natural killer cells